title: [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma].
abstract: In patients up to 70 years of age with colon carcinoma stage III adjuvant chemotherapy with infusions of fluorouracil (5-FU) or oral capecitabine combined with oxaliplatin should be the standard method. A new standard for the palliative treatment of Her2/newly positive advanced gastric cancer and cancer at the gastro-esophageal junction is the administration of trastuzumab combined with chemotherapy. Patients with high-risk soft tissue sarcoma can be helped, in addition to surgical resection and subsequent radiotherapy, by neoadjuvant chemotherapy combined with regional deep hyperthermia. For patients with lung cancer additional individualized treatment is about to become routine. In addition to the EGFR mutation status, all non-smokers should in future be tested for aberration in the anaplastic lymphoma kinase (ALK) gene.
authors.affiliation: Klinik I für Innere Medizin, Uniklinik Köln.
authors.forename: U T
authors.initials: UT
authors.lastname: Hacker
authors.forename: J
authors.initials: J
authors.lastname: Wolf
authors.forename: C-M
authors.initials: CM
authors.lastname: Wendtner
mesh_terms: D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics; D005820:Genetic Testing; D006801:Humans; D006979:Hyperthermia, Induced; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010166:Palliative Care; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D018714:Radiotherapy, Adjuvant; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D012509:Sarcoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013274:Stomach Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000068878:Trastuzumab
chemical_list: D000077548:Anaplastic Lymphoma Kinase; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C000626173:ALK protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human